MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan

MHRA-100799-PIP01-22-M01

Scope of the Application

Active Substance(s)

BEDAQUILINE FUMARATE

Condition(s)

Treatment of multi-drug resistant tuberculosis

Pharmaceutical Form(s)

Tablet, Granules

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

Janssen-Cilag Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Janssen-Cilag Limited submitted to the licensing authority on 07/12/2022 14:37 GMT an application for a Modification

The procedure started on 20/03/2023 17:12 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100799-PIP01-22-M01

Of 31/03/2023 15:15 BST

On the adopted decision for BEDAQUILINE FUMARATE (MHRA-100799-PIP01-22-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for BEDAQUILINE FUMARATE, Tablet, Granules , ORAL USE .

This decision is addressed to Janssen-Cilag Limited, 50-100 Holmers Farm Way, High Wycombe, UNITED KINGDOM, HP12 4DP

ANNEX I

1. Waiver

1.1 Condition:

Not applicable

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of multi-drug resistant tuberculosis

2.2 Indication(s) targeted by the PIP:

Treatment of multi-drug resistant tuberculosis

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

All subsets of the paediatric population from birth to less than 18 years of age

2.4 Pharmaceutical Form(s):

Tablet Granules

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of an age appropriate formulation.
Non-Clinical Studies	1	Study 2 (TMC207-NC119) Juvenile toxicity study in rats.
Clinical Studies	2	Study 3 (TMC207TBC1002) Open label, randomised, crossover study in healthy adult subjects to determine the relative bioavailability of bedaquiline (fumarate) (TMC207) as tablet (for adults) to an age appropriate formulation and to investigate the food effect of the selected paediatric formulation. Study 4 (TMC207-C211) Open-label, multicentre, single arm study to evaluate the pharmacokinetics, safety, tolerability and anti-mycobacterial activity of TMC207 in combination with a background regimen (BR) of multi-drug resistant tuberculosis (MDR-TB) medications for the treatment of children and adolescents from birth to less than 18 years of age who have been diagnosed with confirmed or probable MDR-TB.
Extrapolation, Modeling & Simulation Studies	0	Not applicable.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No

Date of completion of the paediatric investigation plan:	30/11/2026
Deferral of one or more studies contained in the paediatric investigation plan:	Yes